Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

GreenDildos69 Jul. 25 at 6:30 PM

$JSPR the rip is coming

0 · Reply

buysellrepeat Jul. 25 at 6:21 PM

$JSPR looks ready. The algo has probably accumulated enough at this point

0 · Reply

Messerschmittbf109 Jul. 25 at 5:55 PM

$JSPR mediocrity ..new good stock name for jasper 🆕 will be $MDCR. = Mediocrity

0 · Reply

Messerschmittbf109 Jul. 25 at 3:23 PM

$JSPR board strategy is a disaster ..

0 · Reply

Messerschmittbf109 Jul. 25 at 3:22 PM

$JSPR no idea .. bad level of this stock is less than mediocrity

1 · Reply

Messerschmittbf109 Jul. 25 at 3:21 PM

$KIDZ parasites .. for you … nice Week end $SBET $JSPR parasites 🦠….shorts will 🔥

0 · Reply

ProfitMaker4 Jul. 25 at 12:44 PM

$JSPR tough manufacturing errors caused this name to be oversold. I have a LT bullish outlook on JSPR and continue to avg down in the $3.15-$3.40 trading range.

0 · Reply

Messerschmittbf109 Jul. 24 at 7:20 PM

$JSPR shame …..go and become farmers, maybe you have better hands…

0 · Reply

Messerschmittbf109 Jul. 24 at 3:17 PM

$JSPR sh€.. 🥳it management

0 · Reply

Messerschmittbf109 Jul. 24 at 3:16 PM

$JSPR $IMMP resigns ? Same question until the fact

0 · Reply

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 18 days ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 19 days ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 20 days ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 6 weeks ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 7 weeks ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 14, 2025, 4:30 PM EDT - 2 months ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

May 12, 2025, 4:05 PM EDT - 2 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 5 months ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 5 months ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 5 months ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 5 months ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 5 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 6 months ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 7 months ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 7 months ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 8 months ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 8 months ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 9 months ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 9 months ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 9 months ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 10 months ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 10 months ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 11 months ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 4, 2024, 4:30 PM EDT - 11 months ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Jun 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

Jun 17, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

May 30, 2024, 6:05 PM EDT - 1 year ago

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

May 29, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

May 13, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

May 7, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

Apr 2, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Mar 15, 2024, 8:00 AM EDT - 1 year ago

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Mar 4, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

Feb 26, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

Feb 23, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 7, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

Feb 6, 2024, 8:59 AM EST - 1 year ago

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

Feb 5, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 5, 2024, 8:30 AM EST - 1 year ago

Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones

Jan 2, 2024, 8:00 AM EST - 1 year ago

Jasper Therapeutics, Inc. Announces Reverse Stock Split

GreenDildos69 Jul. 25 at 6:30 PM

$JSPR the rip is coming

0 · Reply

buysellrepeat Jul. 25 at 6:21 PM

$JSPR looks ready. The algo has probably accumulated enough at this point

0 · Reply

Messerschmittbf109 Jul. 25 at 5:55 PM

$JSPR mediocrity ..new good stock name for jasper 🆕 will be $MDCR. = Mediocrity

0 · Reply

Messerschmittbf109 Jul. 25 at 3:23 PM

$JSPR board strategy is a disaster ..

0 · Reply

Messerschmittbf109 Jul. 25 at 3:22 PM

$JSPR no idea .. bad level of this stock is less than mediocrity

1 · Reply

Messerschmittbf109 Jul. 25 at 3:21 PM

$KIDZ parasites .. for you … nice Week end $SBET $JSPR parasites 🦠….shorts will 🔥

0 · Reply

ProfitMaker4 Jul. 25 at 12:44 PM

$JSPR tough manufacturing errors caused this name to be oversold. I have a LT bullish outlook on JSPR and continue to avg down in the $3.15-$3.40 trading range.

0 · Reply

Messerschmittbf109 Jul. 24 at 7:20 PM

$JSPR shame …..go and become farmers, maybe you have better hands…

0 · Reply

Messerschmittbf109 Jul. 24 at 3:17 PM

$JSPR sh€.. 🥳it management

0 · Reply

Messerschmittbf109 Jul. 24 at 3:16 PM

$JSPR $IMMP resigns ? Same question until the fact

0 · Reply

buysellrepeat Jul. 24 at 4:44 AM

$JSPR worth a second look

0 · Reply

BinaryLogic Jul. 24 at 12:50 AM

$ABCL $JSPR $OCGN $VTYX $RCKT

0 · Reply

GreenDildos69 Jul. 23 at 2:54 PM

$JSPR volume picking up

0 · Reply

yung_priest_ Jul. 23 at 2:02 PM

$JSPR Can we get some good news please?

0 · Reply

Messerschmittbf109 Jul. 22 at 6:16 PM

$JSPR $IMMP $INO When….after chronic losses in capital value and zero discoveries of new drugs on the market, they don't have the courage to change board members, it means they don't care about the shareholders. Total disappointment, even in terms of the hope of discovering new drugs.

0 · Reply

Messerschmittbf109 Jul. 22 at 3:07 PM

$SBET shorts. = bad ill = cancer $AIRE $JSPR $EPWK

0 · Reply

DarkOrb Jul. 21 at 5:36 PM

$JSPR How long does it take to investigate a drug lot when your company's survival is at stake? Two weeks since the trial update. I would think we'd get an update soon, but I have no idea. Their release was quite vague on when they expected to update investors.

1 · Reply

Messerschmittbf109 Jul. 21 at 4:28 PM

$JSPR $IMMP They are shamefully glued to their chairs. They have only created losses for the shareholders and not a single drug.

0 · Reply

Messerschmittbf109 Jul. 21 at 4:12 PM

$JSPR $IMMP boring loss days

0 · Reply

Dahoom93 Jul. 21 at 1:50 PM

$JSPR .

0 · Reply

yung_priest_ Jul. 21 at 1:36 PM

$JSPR

0 · Reply

GreenDildos69 Jul. 21 at 12:47 PM

$JSPR

0 · Reply

Market Cap	47.32M
Revenue (ttm)	0.00
Net Income (ttm)	-71.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	250,400
Avg Vol	735,466
Day's Range	N/A - N/A
Shares Out	15.02M
Stochastic %K	19%
Beta	2.69
Analysts	Strong Sell
Price Target	$16.29